InnovAge Holding Corp. (INNV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented strong financial results with a 15% revenue increase and a significant improvement in adjusted EBITDA. Despite challenges like higher costs and regulatory risks, the company achieved its first positive net income since 2021. The Q&A highlighted confidence in guidance and effective cost management, though some responses lacked clarity. Overall, the optimistic financial performance and strategic focus on operational efficiency suggest a positive stock price movement in the near term.
Key Financial Performance
Total Revenue $236.1 million, a 15% increase year-over-year. This growth was driven by an increase in member months and capitation rates, particularly in California, Florida, and Colorado centers.
Adjusted EBITDA $17.6 million, more than doubled year-over-year. This improvement reflects strong medical cost management and better-than-expected census growth.
Census 7,890 participants, a 9.4% increase year-over-year and a 1.9% sequential quarter growth. Growth was driven by reinstating participants who lost Medicaid coverage and timing delays in disenrollment.
Net Income $7.7 million compared to a net loss of $5.7 million in the prior year. This marks the first positive net income since 2021, attributed to disciplined execution and cost management.
External Provider Costs $108.9 million, a 1.5% increase year-over-year. The increase was driven by higher member months but offset by a decrease in cost per participant due to lower nursing facility utilization and pharmacy expense.
Cost of Care (Excluding Depreciation and Amortization) $75.9 million, a 19.7% increase year-over-year. This was due to higher salaries, wages, and benefits, as well as increased costs associated with in-house pharmacy services and transportation.
Center-Level Contribution Margin $51.4 million, an increase from $41.3 million in the prior quarter. As a percentage of revenue, it increased to 21.8% from 18.6%.
Sales and Marketing Expenses $7.6 million, a 17.1% increase year-over-year. This was due to increased headcount, wage rates, and marketing spend to support growth.
Corporate, General, and Administrative Expenses $30.3 million, a 9.9% increase year-over-year. This was driven by higher employee compensation, software license fees, and professional services, partially offset by lower legal fees.
Adjusted EBITDA Margin 7.5%, compared to 3.2% in the prior year. This reflects improved operational efficiency and cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Florida Centers: Positive momentum in new Florida centers, particularly in Tampa, with a strong partnership with Tampa General.
PACE Model Resilience: PACE model remains resilient compared to other value-based care models, offering a fully integrated care approach for dual eligibles.
Market Expansion: InnovAge is the largest PACE provider in the U.S., serving nearly 8,000 participants across 20 centers in 6 states.
Cost Management: Achieved a decline in total participant expense per month sequentially compared to Q4 FY2025, driven by better medical cost management.
Operational Improvements: Streamlined shared services workforce, reduced management layers, and improved decision-making speed through spans and layers review.
In-sourcing Key Services: Strategically in-sourced pharmacy and hospice services to tighten cost control and improve coordination.
Leadership Changes: New leadership appointments, including Dr. Paul Taheri as Chief Medical Officer and Meredith Delk as Chief Administrative Officer, to strengthen operations.
Growth Strategy: Executing a multipronged growth strategy, including joint ventures, M&A, and de novo centers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Operating Environment Challenges: The operating environment for value-based care models remains challenging due to lower or declining reimbursement levels, higher-than-expected medical service utilization, and growing regulatory scrutiny around risk adjustment and quality measures.
Medicaid Redetermination Delays: Enrollment and redetermination processing delays in Medicaid could impact participant census and revenue stability.
Leadership Transitions: Recent leadership changes, including the departure of the President and COO, could pose risks to operational continuity and strategic execution.
Cost Pressures: Increased costs per participant driven by higher salaries, wages, benefits, and fleet costs, as well as higher assisted living and nursing facility unit costs, could pressure margins.
De Novo Center Losses: Losses from new centers (de novo centers) in Tampa and Orlando, totaling $3.9 million for the quarter, could weigh on overall profitability.
Regulatory and Compliance Risks: Growing regulatory scrutiny and the need to maintain compliance with Medicare and Medicaid requirements could increase operational complexity and costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal Year 2026 Guidance: InnovAge reaffirmed its fiscal year 2026 guidance, projecting an ending census of 7,900 to 8,100 participants and member months in the range of 91,600 to 94,400. Total revenue is expected to be between $900 million and $950 million, with adjusted EBITDA in the range of $56 million to $65 million. De novo losses for fiscal year 2026 are anticipated to be between $13.4 million and $15.4 million.
Revenue Growth: Total revenue is projected to grow, driven by increases in member months and capitation rates, with annual rate increases in Colorado, New Mexico, Virginia, and Medicare effective July 1, 2025.
Cost Management: InnovAge expects to continue benefiting from cost management initiatives, including reduced external provider costs per participant due to lower utilization of nursing facilities and pharmacy expense reductions from in-house pharmacy services.
Operational Adjustments: The company has implemented organizational changes, including a spans and layers review, to streamline support functions and reduce management layers. These changes are expected to improve decision-making speed, enhance accountability, and align cost structures with industry benchmarks.
De Novo Centers: De novo center losses are expected to range between $13.4 million and $15.4 million for fiscal year 2026, primarily related to the Tampa and Orlando centers in Florida.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company thinking about margin progression for the remainder of the year under the reaffirmed guidance setup?
A:The company does not provide quarterly guidance but highlighted several factors influencing margin progression. These include Medicaid eligibility changes, Medicare fee schedule increases, risk score decay, merit increases, and higher utilization during cold and flu season. The first quarter saw some lumpiness due to Medicaid eligibility issues, but the company remains confident in its guidance.
Q:How does the company view the competitive dynamics of the current cycle, particularly with the uptick in Special Needs Plans offerings?
A:The market remains competitive, with Special Needs Plans maintaining a strong presence. The company has focused on differentiating its PACE offering by emphasizing its comprehensive and integrated benefits compared to Medicare Advantage plans. The company feels good about its market positioning and has improved its ability to articulate the value proposition of PACE.
Q:What are the cost trends reported, and what factors contributed to the lower SNF utilization?
A:The company has optimized discharges from hospitals to appropriate care levels, reduced unnecessary SNF admissions, and aligned incentives with network partners. Clinical value initiatives, such as managing inpatient hospitalizations, readmissions, and pharmacy costs, have contributed to cost savings. The in-housing of pharmacy has also shifted some expenses, impacting cost trends.
Q:How far along is the company in standardizing clinical value initiatives, and what is the potential for further improvement?
A:The company estimates it is about 50% along the path of standardizing clinical value initiatives. Future improvements include reducing care variation, implementing technology-based clinical guidelines, and addressing resistance to change. The company has brought in leadership to help achieve these goals over the next few years.
Q:Review of Unclear Management Responses
A:Management avoided providing direct quarterly guidance for margin progression, instead offering a broad overview of influencing factors. Additionally, while discussing cost trends, the explanation of expense shifts due to the in-housing of pharmacy lacked detailed clarity, making it difficult to fully understand the financial impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Administrative Officer
CEO quarter
COO end
Chief Administrative
Congress MACPAC
DNA progress
Dr leader
EMR Oracle
General start
InnovAge PACE
InnovAge destination
InnovAge provider
Medicaid redetermination
PACE model
accountability
addition
care model
center level
change
conference
coordination
discipline
family
home
job
layer
life
outcome
peace mind
satisfaction
scale
seasonality cost
senior
structure
support
talent
week
worry
INNV Transcript
InnovAge Holding Corp. (INNV) Q3 2026 Earnings Call Transcript
Unknown5-5
The earnings call presents a mixed outlook. The positive aspects include a 5% revenue increase and improved EBITDA due to cost optimizations. However, the 20% decline in net income and increased operating expenses raise concerns. The raised fiscal 2026 guidance and improved Medicaid rates are positive, but Medicare rate pressures and ongoing legal proceedings pose risks. Given these mixed signals and absent market cap information, a neutral sentiment is appropriate, reflecting potential stability rather than significant movement in stock price.
InnovAge Holding Corp. (INNV) Q2 2026 Earnings Call Transcript
Positive2-3
The earnings call reveals strong financial performance, with substantial revenue growth, improved EBITDA, and a positive net income shift. Despite some challenges, such as Q3 seasonal pressures, guidance remains optimistic with strong census growth and cost management. The Q&A highlights effective internal processes and a proactive approach to Medicaid coverage. However, management's vague responses on certain metrics and the seasonal Q3 impact temper the outlook slightly. Overall, the sentiment is positive, driven by robust financials and strategic improvements, suggesting a stock price increase in the 2% to 8% range.
InnovAge Holding Corp. (INNV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
InnovAge Holding Corp. (INNV) Q1 2026 Earnings Call Transcript
Positive11-4
The earnings call presented strong financial results with a 15% revenue increase and a significant improvement in adjusted EBITDA. Despite challenges like higher costs and regulatory risks, the company achieved its first positive net income since 2021. The Q&A highlighted confidence in guidance and effective cost management, though some responses lacked clarity. Overall, the optimistic financial performance and strategic focus on operational efficiency suggest a positive stock price movement in the near term.
INNV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
